Thyroid Cancer - Pipeline Review, H2 2017

Date: September 12, 2017
Pages: 490
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: TADA7BFCA39EN
Leaflet:

Download PDF Leaflet

Thyroid Cancer - Pipeline Review, H2 2017
Thyroid Cancer - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thyroid Cancer - Pipeline Review, H2 2017, provides an overview of the Thyroid Cancer (Oncology) pipeline landscape.

Thyroid cancer is a cancer that starts in the thyroid gland. Symptoms include lump that can be felt through the skin on neck, difficulty swallowing, pain in neck and throat and swollen lymph nodes in neck. Predisposing factors include female, high levels of radiation and inherited genetic syndromes. Treatment includes surgery and thyroid hormone therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thyroid Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Thyroid Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thyroid Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Thyroid Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 33, 28, 1, 11 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 3 and 5 molecules, respectively.

Thyroid Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Thyroid Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Thyroid Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Thyroid Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Thyroid Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Thyroid Cancer (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Thyroid Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Thyroid Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Thyroid Cancer - Overview
Thyroid Cancer - Therapeutics Development
Thyroid Cancer - Therapeutics Assessment
Thyroid Cancer - Companies Involved in Therapeutics Development
Thyroid Cancer - Drug Profiles
Thyroid Cancer - Dormant Projects
Thyroid Cancer - Discontinued Products
Thyroid Cancer - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Thyroid Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Thyroid Cancer - Pipeline by AbbVie Inc, H2 2017
Thyroid Cancer - Pipeline by Advenchen Laboratories LLC, H2 2017
Thyroid Cancer - Pipeline by AstraZeneca Plc, H2 2017
Thyroid Cancer - Pipeline by Bayer AG, H2 2017
Thyroid Cancer - Pipeline by BeiGene Ltd, H2 2017
Thyroid Cancer - Pipeline by Biovista Inc, H2 2017
Thyroid Cancer - Pipeline by Blueprint Medicines Corp, H2 2017
Thyroid Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Thyroid Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2017
Thyroid Cancer - Pipeline by Celldex Therapeutics Inc, H2 2017
Thyroid Cancer - Pipeline by Centrose LLC, H2 2017
Thyroid Cancer - Pipeline by Curis Inc, H2 2017
Thyroid Cancer - Pipeline by Cytori Therapeutics Inc, H2 2017
Thyroid Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2017
Thyroid Cancer - Pipeline by Ecrins Therapeutics SAS, H2 2017
Thyroid Cancer - Pipeline by Eisai Co Ltd, H2 2017
Thyroid Cancer - Pipeline by Ensol Biosciences Inc, H2 2017
Thyroid Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Thyroid Cancer - Pipeline by Genelux Corp, H2 2017
Thyroid Cancer - Pipeline by Genmab A/S, H2 2017
Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H2 2017
Thyroid Cancer - Pipeline by Gradalis Inc, H2 2017
Thyroid Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2017
Thyroid Cancer - Pipeline by Ignyta Inc, H2 2017
Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2017
Thyroid Cancer - Pipeline by Immunomedics Inc, H2 2017
Thyroid Cancer - Pipeline by Johnson & Johnson, H2 2017
Thyroid Cancer - Pipeline by Konruns Pharmaceutical Co Ltd, H2 2017
Thyroid Cancer - Pipeline by Loxo Oncology Inc, H2 2017
Thyroid Cancer - Pipeline by MacroGenics Inc, H2 2017
Thyroid Cancer - Pipeline by MaxiVAX SA, H2 2017
Thyroid Cancer - Pipeline by MedImmune LLC, H2 2017
Thyroid Cancer - Pipeline by Merck & Co Inc, H2 2017
Thyroid Cancer - Pipeline by Merck KGaA, H2 2017
Thyroid Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Thyroid Cancer - Pipeline by Nerviano Medical Sciences Srl, H2 2017
Thyroid Cancer - Pipeline by Novartis AG, H2 2017
Thyroid Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017
Thyroid Cancer - Pipeline by Pfizer Inc, H2 2017
Thyroid Cancer - Pipeline by Plexxikon Inc, H2 2017
Thyroid Cancer - Pipeline by Rodos BioTarget GmbH, H2 2017
Thyroid Cancer - Pipeline by Synactix Pharmaceuticals Inc, H2 2017
Thyroid Cancer - Pipeline by Tarveda Therapeutics Inc, H2 2017
Thyroid Cancer - Pipeline by Vaccinex Inc, H2 2017
Thyroid Cancer - Pipeline by Vascular Biogenics Ltd, H2 2017
Thyroid Cancer - Pipeline by XSpray Microparticles AB, H2 2017
Thyroid Cancer - Dormant Projects, H2 2017
Thyroid Cancer - Dormant Projects, H2 2017 (Contd..1), H2 2017
Thyroid Cancer - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Thyroid Cancer, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

AbbVie Inc
Advenchen Laboratories LLC
AstraZeneca Plc
Bayer AG
BeiGene Ltd
Biovista Inc
Blueprint Medicines Corp
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Celldex Therapeutics Inc
Centrose LLC
Curis Inc
Cytori Therapeutics Inc
Daiichi Sankyo Company Ltd
Ecrins Therapeutics SAS
Eisai Co Ltd
Ensol Biosciences Inc
F. Hoffmann-La Roche Ltd
Genelux Corp
Genmab A/S
GlaxoSmithKline Plc
Gradalis Inc
Hutchison MediPharma Ltd
Ignyta Inc
Immune Pharmaceuticals Inc
Immunomedics Inc
Johnson & Johnson
Konruns Pharmaceutical Co Ltd
Loxo Oncology Inc
MacroGenics Inc
MaxiVAX SA
MedImmune LLC
Merck & Co Inc
Merck KGaA
Millennium Pharmaceuticals Inc
Nerviano Medical Sciences Srl
Novartis AG
Ono Pharmaceutical Co Ltd
Pfizer Inc
Plexxikon Inc
Rodos BioTarget GmbH
Synactix Pharmaceuticals Inc
Tarveda Therapeutics Inc
Vaccinex Inc
Vascular Biogenics Ltd
XSpray Microparticles AB
Skip to top


Thyroid Cancer - Pipeline Review, H1 2017 US$ 2,000.00 Mar, 2017 · 383 pages
Papillary Thyroid Cancer - Pipeline Review, H2 2016 US$ 2,000.00 Sep, 2016 · 72 pages
Follicular Thyroid Cancer - Pipeline Review, H1 2016 US$ 2,000.00 Feb, 2016 · 83 pages
Papillary Thyroid Cancer - Pipeline Review, H1 2016 US$ 2,000.00 Apr, 2016 · 106 pages
Rectal Cancer - Pipeline Review, H2 2017 US$ 2,000.00 Aug, 2017 · 128 pages

Ask Your Question

Thyroid Cancer - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: